Skip to main content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.covid19.nih.gov

Grant Details

Grant Number: 5R21CA143170-03 Interpret this number
Primary Investigator: Hall, Susan
Organization: New England Research Institutes, Inc.
Project Title: Exogenous Testosterone and Risk of Cancer
Fiscal Year: 2012


Abstract

6. PROJECT SUMMARY/ABSTRACT Since the 1940s, it has been generally accepted in the medical community that the growth of prostate cancer is androgen-dependent,3 and prostate cancer risk is the primary safety concern with use of exogenous testosterone.4, 5 Prescription testosterone has been available in the U.S. for more than 50 years, but patterns of uptake have recently changed. U.S. sales of testosterone have increased more than 1500% considering 1994-2002, with sharp increases in the most recent years.6 Researchers have noted that the increase in uptake is occurring in the absence of changes in recommendations for testosterone use,7 e.g., an expansion of approved indications. There is very little information regarding the characteristics of users, and clinical trials have not provided long-term safety data regarding the prostate cancer risk of testosterone products.5, 6 There have been no prior epidemiologic studies of exogenous testosterone products and prostate cancer risk, possibly because of the large number of men needed to capture sufficient numbers exposed to testosterone. The research intent of this application is to cost-efficiently use a unique existing resource, the Saskatchewan Health Services Databases, in order to fill the knowledge gap surrounding exogenous testosterone use and prostate cancer and deliver the first population-based epidemiologic study on this topic. The provincial government of Saskatchewan provides health coverage to nearly all residents, and the existing data contain >500,000 males and >30 years of observation time from a defined geographic area, with cancer outcome information available from a provincial cancer registry.57, 58, 105 Testosterone exposures are captured in electronic prescribing records and are not subject to error based on patient recall, with dose and duration of use available. We plan to use a retrospective, matched cohort study design and longitudinal analysis methods to estimate the risk of prostate cancer incidence and recurrence, incidence of severe prostate cancer, prostate cancer mortality, and breast cancer incidence among males exposed to exogenous testosterone compared to age- matched males not exposed. We will also descriptively examine patterns of testosterone use to better understand the characteristics of users. The diverse expertise of the research team includes pharmacoepidemiology, biostatistics, clinical endocrinology, and oncology, and the team has a demonstrated history of manuscript productivity relevant to the publication plans of the project. The public health relevance of the proposal is high, given the increasing using of testosterone as 'hormone replacement therapy' and the potential for newly repeating 'the estrogen disaster' among women for prostate cancer among men.16 The clinical implications for the patient are a cessation of testosterone therapy, if increased risks are found. Regardless of the direction of results, our findings will serve the federal health goals of pharmacovigilance for marketed medications.17



Publications

Population-based patterns of prescription androgen use, 1976-2008.
Authors: Hall S.A. , Ranganathan G. , Tinsley L.J. , Lund J.L. , Kupelian V. , Wittert G.A. , Kantoff P.W. , Morales A. , Araujo A.B. .
Source: Pharmacoepidemiology and drug safety, 2014 May; 23(5), p. 498-506.
EPub date: 2014-02-07.
PMID: 24510484
Related Citations




Back to Top